Department of Neurology, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Int J Stroke. 2018 Dec;13(9):913-920. doi: 10.1177/1747493018798557. Epub 2018 Sep 3.
This review provides an update of evidence on post-stroke infections and the use of preventive antibiotics in stroke. Infection is a common complication after stroke, affecting between 15% and 30% of the patients. The predictors for post-stroke infection can be divided into three categories: clinical factors, anatomical (stroke related) factors and immunological factors. The relation between the occurrence of a post-stroke infection and functional outcome remained subject of debate, but it seems likely that the occurrence of these infections has a causal relation with poor functional outcome and mortality. In the first meta-analysis on preventive antibiotic therapy, almost a decade ago, its beneficial effect on post-stroke infection rate was clear; however, the effect on functional outcome remained uncertain because included studies were small and heterogeneous. Afterwards, three large phase-3 RCTs were published and a Cochrane meta-analysis was performed. It has now become clear that, despite the finding that overall infections are reduced, preventive antibiotic therapy in the acute phase of stroke does neither improve functional outcome, nor decrease mortality rates. This does not yet mean that further research on preventive antibiotics in stroke is useless: the pathophysiology and etiology of post-stroke infections are unclear and the use of preventive antibiotics in specific subgroups of stroke patients could still be very effective. This is currently being studied. Besides, preventive antibiotic therapy might be cost-effective by increasing quality-adjusted life years. Thirdly, research for the upcoming years might put more emphasis on the effect of stroke on immunological alterations.
这篇综述更新了卒中后感染和预防性使用抗生素的证据。感染是卒中后的常见并发症,影响 15%至 30%的患者。卒中后感染的预测因素可分为三类:临床因素、解剖(卒中相关)因素和免疫因素。卒中后感染的发生与功能结局之间的关系仍存在争议,但这些感染的发生似乎与不良功能结局和死亡率有因果关系。在近十年前首次关于预防性抗生素治疗的荟萃分析中,其对卒中后感染率的有益影响是明确的;然而,对功能结局的影响仍不确定,因为纳入的研究规模较小且存在异质性。之后,三项大型 3 期 RCT 发表,并且进行了 Cochrane 荟萃分析。现在已经清楚的是,尽管发现总体感染减少,但卒中急性期的预防性抗生素治疗既不能改善功能结局,也不能降低死亡率。这并不意味着进一步研究卒中的预防性抗生素是无用的:卒中后感染的病理生理学和病因尚不清楚,预防性抗生素在卒中患者的特定亚组中可能仍然非常有效。目前正在进行研究。此外,预防性抗生素治疗可能通过增加质量调整生命年来具有成本效益。第三,未来几年的研究可能会更加关注卒中对免疫改变的影响。